Hostname: page-component-745bb68f8f-grxwn Total loading time: 0 Render date: 2025-01-25T11:16:43.926Z Has data issue: false hasContentIssue false
  • English
  • Français

From Pharmaceutical Innovation to Revenue Generation: The Asian Experience

Published online by Cambridge University Press:  29 December 2023

Subir Kumar Basak
Subir Kumar Basak*
Affiliation:
SUBIR KUMAR BASAK, IFC, WORLD BANK GROUP, WASHINGTON, DC, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

Asia’s pharmaceutical sector has experienced remarkable growth over the last two decades, with companies in the region producing bulk of the world’s specialty generics, biologicals, and active pharmaceutical ingredients (APIs). The Asian pharma growth story has had several pillars for a strong and sustainable foundation that provided non-linear growth. This report introduces three models showing how Asian countries at different development stages — India, South Korea, and Singapore — have nurtured their own, self-sustaining pharmaceutical sectors.

Keywords

Pharmaceutical InnovationLatin AmericaAsia
Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 51 , Issue S1: Rethinking Pharmaceutical Policies in Latin America and the Caribbean , Fall 2023 , pp. 62 - 75
Copyright
© 2023 The Author(s)

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Hikino, T., Amsden, A.H., and Wolfson, L., “Late Industrialization in Historical Perspective,” Economic Development 35, no. 137 (1995): 3–34; L. Kim, Imitation to Innovation: The Dynamics of Korea’s Technological Learning (Cambridge: Harvard Business Press, 1997); L. Kim, “The Dynamics of Technological Learning in Industrialization,” International Social Science Journal 53, no. 16 (2001): 297-308.Google Scholar
S. Mladenov, “EMIS Insights, Latin America Pharma and Healthcare Sector 2021/2025,” 2021, available at <https://interactive.emis.com/latin-america-pharma-healthcare-2021-2025> (last visited September 1, 2023); V. Vargas, M. Rama, and R. Singh et al., “Pharmaceuticals in Latin America and the Caribbean: Players, Access, and Innovation Across Diverse Models,” World Bank, 2022, available at <http://hdl.handle.net/10986/36871> (last visited September 1, 2023).+(last+visited+September+1,+2023);+V.+Vargas,+M.+Rama,+and+R.+Singh+et+al.,+“Pharmaceuticals+in+Latin+America+and+the+Caribbean:+Players,+Access,+and+Innovation+Across+Diverse+Models,”+World+Bank,+2022,+available+at++(last+visited+September+1,+2023).>Google Scholar
Adhia, N., “The History of Economic Development in India Since Independence,” Education about Asia 20, no. 3 (2015): 18–22, available at <https://www.asianstudies.org/publications/eaa/archives/the-history-of-economic-development-in-india-since-independence/> (last visited September 1, 2023).Google Scholar
W. Greene, “The Emergence of India’s Pharmaceutical Industry and Implications for the US Generic Drug Market,” US Trade Commission, May 2007, available at < https://www.usitc.gov/publications/332/EC200705A.pdf> (last visited September 1, 2023).+(last+visited+September+1,+2023).>Google Scholar
Drabu, H., “Status of Drug Industry in India,” Economic and Political Weekly 21, no. 5 (1986): 194–196.Google Scholar
Ministry of Pharmaceuticals, India, 1979, available at <https://pharmaceuticals.gov.in/sites/default/files/DPCO1979.pdf> (last visited October 25, 2023).+(last+visited+October+25,+2023).>Google Scholar
India Brand Equity Foundation (IBEF), “Biotechnology Industry in India,” available at <https://www.ibef.org/industry/biotechnology-india> (last visited September 1, 2023).+(last+visited+September+1,+2023).>Google Scholar
See Greene, supra note 4.Google Scholar
Niosi, J., Hanel, P., and Reid, S., “The International Diffusion of Biotechnology: The Arrival of Developing Countries,” Journal of Evolutionary Economics 22, no. 4 (2012): 767–83.Google Scholar
Niosi, J., “Imitation and Innovation New Biologics, Biosimilars and Biobetters,” Technology Analysis & Strategic Management 29, no. 3 (2017): 251–262.Google Scholar
R. Gupta, “India’s Economic Ambitions in the Pharmaceutical Industry,” Asia Dispatches, Wilson Center, 2022, available at <https://www.wilsoncenter.org/blog-post/indias-economic-ambitions-pharmaceutical-industry> (last visited September 1, 2023).+(last+visited+September+1,+2023).>Google Scholar
Id. Google Scholar
PriceWaterhouseCoopers PWC Report, “Global Pharma Looks to India: Prospects for Growth,” 2020, available at <https://www.pwc.com/gx/en/pharma-life-sciences/pdf/global-pharma-looks-to-india-final.pdf> (last visited September 1, 2023).+(last+visited+September+1,+2023).>Google Scholar
D. Jeantet and D. Biller, “Brazil Receives Vaccine Cargo from India Amid Supply Concern,” AP News, January 22, 2021, available at <https://apnews.com/article/public-health-brazil-rio-de-janeiro-health-south-america-e013b5193bf6a38471b3ab80aa8410d4> (last visited September 1, 2023).+(last+visited+September+1,+2023).>Google Scholar
H. Seshasayee, “India and Latin America: Moving from Transactional to Permanent Healthcare Partners,” Georgetown Journal of International Affairs, March 18 2021, available at <https://gjia.georgetown.edu/2021/03/18/india-and-latin-america-moving-from-transactional-to-permanent-healthcare-partners/> (last visited September 1, 2023).+(last+visited+September+1,+2023).>Google Scholar
E. Marchan, “India-Brazil Pioneers of a New Development Agenda,” Gateway House, March 13, 2012, available at <https://www.gatewayhouse.in/india-brazil-pioneers-new-development-agenda/> (last visited September 1, 2023).+(last+visited+September+1,+2023).>Google Scholar
V. Vargas, “Analysis of Regional Capacity for Research, Development, and Manufacturing of Vaccines in Latin America and the Caribbean,” November 15, 2020, available at <https://www.researchgate.net/publication/349110196_Analysis_of_Regional_Capacity_for_Research_Development_and_Manufacturing_of_Vaccines_in_Latin_America_and_the_Caribbean> (last visited September 1, 2023).+(last+visited+September+1,+2023).>Google Scholar
Global Data, n.d., available at <https://www.globaldata.com/store/report/impact-of-south-korea-on-pharmaceutical-industry-theme-analysis/> (last visited October 25, 2023).+(last+visited+October+25,+2023).>Google Scholar
S. Cho, “Biotechnology Trends in Korea,” 2013, available at <https://www.conicyt.cl/wp-content/blogs.dir/26/files/2013/11/Biotechnology-Trends-in-Korea.pdf> (last visited October 25, 2023).+(last+visited+October+25,+2023).>Google Scholar
Swinbanks, D., “Korea Holds Firm to Biotech Expansion,” Nature 390, no. 213 (1997): available at <https://www.nature.com/articles/36685> (last visited September 1, 2023).10.1038/36685CrossRefGoogle ScholarPubMed
A. Saegusa, “Biotechnology Unscathed in Korean Finance Crisis?” Nature Biotechnology 16 (February 1998), available at <https://www.nature.com/articles/nbt0298-151.pdf> (last visited September 4, 2023).+(last+visited+September+4,+2023).>Google Scholar
Ministry of Science and Technology, “Bio-vision 2016 Unveiled,” Newswire, November 15, 2006, available at <https://www.newswire.co.kr/newsRead.php?no=203492> (last visited September 1, 2023).+(last+visited+September+1,+2023).>Google Scholar
Lavarello, P., Sztulwark, S., Mancini, M., and Juncal, S., “Creative Imitation in Late Industrializing Countries: The Case of Biopharmaceutics in South Korea and India,” Innovation and Development 13, no. 1 (2023): 133–152.Google Scholar
Korea Drug Development Fund, available at <https://www.khidi.or.kr/fileDownload?titleId=259069&fileId=1&fileDownType=C&paramMenuId=MENU01847asKDDF.pdf> (last visited October 25, 2023).+(last+visited+October+25,+2023).>Google Scholar
KORUS FTA, available at <https://www.cbp.gov/trade/free-trade-agreements/korea> (last visited October 25, 2023).+(last+visited+October+25,+2023).>Google Scholar
KORUS FTA.Google Scholar
M. Chang, “Can Open Innovation, R&D Tax Support Produce Korea’s Next Blockbuster Drug?” Korea Biomedical Review, May 9, 2023, available at <https://www.koreabiomed.com/news/articleView.html?idxno=21054> (last visited September 4, 2023).+(last+visited+September+4,+2023).>Google Scholar
Samsung Biologics and Biogen Idec Announce Formation of Biosimilars Joint Venture Samsung Bioepis, Biogen Corporate Pess Release, February 27, 2012, available at <https://investors.biogen.com/news-releases/news-release-details/samsung-biologics-and-biogen-idec-announce-formation-biosimilars> (last visited September 1, 2023).+(last+visited+September+1,+2023).>Google Scholar
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy, Bloomberg Press Release, August 4, 2020, available at <https://www.bloomberg.com/press-releases/2020-08-04/merck-and-hanmi-pharmaceutical-enter-into-licensing-agreement-to-develop-efinopegdutide-an-investigational-once-weekly-therapy> (last visited September 1, 2023).+(last+visited+September+1,+2023).>Google Scholar
The Pharma 1000, “Top Global Pharma Company Report,” Torreya Capital LLC presentation, November 2021.Google Scholar
Better Policies Series, Korea: Policy Priorities for a Dynamic, Inclusive and Creative Economy, OECD, October 2015, available at <https://www.oecd.org/korea/korea-policy-priorities-for-a-dynamic-inclusive-and-creative-economy-EN.pdf> (last visited September 7, 2023).+(last+visited+September+7,+2023).>Google Scholar
Id. Google Scholar
N. Gupta, D.W. Healey, A.M. Stein, S.S. Shipp et al., Innovation policies of Korea, Institute for Defense Analyses, IDA document D-4984, 2013, available at <https://www.wilsoncenter.org/sites/default/files/media/documents/event/IDA%20Document%20D-4984%20FINAL%20Korea%20Innovation%20Policies.pdf> (last visited September 7, 2023).+(last+visited+September+7,+2023).>Google Scholar
Id. Google Scholar
Shin, Y.S., “Past, Present and Future of Pharmaceuticals Patents under Korea-US Trade Agreement,” Pharmaceutical Patent Analysis 5, no. 4 (2016) 237–48, 2016.10.4155/ppa-2016-0013CrossRefGoogle ScholarPubMed
Choi, N. and Son, K.-B., “Perceived Impact of the Patent Linkage System on Pharmaceutical Market from the Viewpoint of the Domestic Manufacturers in South Korea,” Globalization and Health 18, no. 34 (2022), available at <https://globalizationandhealth.biomedcentral.com/articles/10.1186/s12992-022-00829-1> (last visited September 7, 2023).10.1186/s12992-022-00829-1CrossRefGoogle ScholarPubMed
Korea Drug Research Associaton website, available at < https://www.kdra.or.kr/english/03web01.php> (last visited October 23, 2023).+(last+visited+October+23,+2023).>Google Scholar
S.K. Biopharmaceuticals Press Release, November 21, 2019, available at <https://www.sklifescienceinc.com/pdf/FDA_Approves_XCOPRI_(cenobamate_tablets)_an_Anti-Epileptic_Drug_(AED)_from_SK_Biopharmaceuticals_Co._Ltd._and_U.S._Subsidiary_SK_Life_Science_Inc.pdf> (last visited September 7, 2023).+(last+visited+September+7,+2023).>Google Scholar
SK Group Chairman Celebrates Growing U.S. Partnerships at SK Night, PR Newswire, September 22 2022, available at <https://www.prnewswire.com/news-releases/sk-group-chairman-celebrates-growing-us-partnerships-at-sk-night-301630549.html> (last visited September 7, 2023).+(last+visited+September+7,+2023).>Google Scholar
L. Han-Soo, “Celltrion’s 2022 Sales May Exceed ₩2 Trillion After Robust 3Q Sales,” Korea Biomedical Review, November 2022, available at <https://www.koreabiomed.com/news/articleView.html?idxno=15011> (last visited September 7, 2023).+(last+visited+September+7,+2023).>Google Scholar
See Korea Drug Research Association, supra note 37.Google Scholar
K. Dunleavy, “In $500M Expansion, Merck Opens One Singapore Facility and Breaks Ground on Another,” Fierce Pharma, October 5 2022, available at <https://www.fiercepharma.com/manufacturing/merck-opens-one-manufacturing-facility-singapore-breaks-ground-another> (last visited September 7, 2023).+(last+visited+September+7,+2023).>Google Scholar
J. Pomager, “Singapore Gets It First Biotech Company,” Pharmaceutical Online, June 19 2000, available at <https://www.pharmaceuticalonline.com/doc/singapore-gets-its-first-biotech-company-0001> (last visited September 7, 2023).+(last+visited+September+7,+2023).>Google Scholar
Swan, B., “Singapore’s Biomedical Sciences Strategy,” BioProcess Journal 3, no. 3 (2004): 20–21.Google Scholar
W. Arnold, “Singapore Goes Biotech,” New York Times, August 26, 2003, available at <https://www.nytimes.com/2003/08/26/business/singapore-goes-for-biotech.html> (last visited September 7, 2023).+(last+visited+September+7,+2023).>Google Scholar
National Research Foundation, Singapore, available at <https://www.nrf.gov.sg/> (last visited September 7, 2023).+(last+visited+September+7,+2023).>Google Scholar
Human Resources Director, “Attach and Train Initiative Aims to Improve Jobseekers Prospects,” Asia News, February 22, 2017, available at <https://www.hcamag.com/asia/news/general/attach-and-train-initiative-aims-to-improve-jobseekers-prospects/148169> (last visited September 7, 2023).+(last+visited+September+7,+2023).>Google Scholar
T.S. Kit, “New Scheme to Help 300 Mid-Career PMETs Enter Biomedical Science Sector over the Next Year,” Channel News Asia, August 26, 2020.Google Scholar
L. Killen, M. Palladino, and F. Gonzalez, et al., Singapore’s Biomedical Cluster, Cambridge Industrial Innovation Policy, University of Cambridge, February 2021, available at <https://www.ciip.group.cam.ac.uk/reports-and-articles/singapores-biomedical-cluster/download/2021-02-19-SBS.pdf> (last visited September 7, 2023).+(last+visited+September+7,+2023).>Google Scholar
EDB Singapore, available at <https://www.edb.gov.sg/en/our-industries/pharmaceuticals-and-biotechnology.html> (last visited September 7, 2023).+(last+visited+September+7,+2023).>Google Scholar
Ministry of Foreign Affairs, “Latin America,” available at <https://www.mfa.gov.sg/SINGAPORES-FOREIGN-POLICY/Countries-and-Regions/Americas/Latin-America> (last visited September 7, 2023).+(last+visited+September+7,+2023).>Google Scholar